PERTH, Australia – Melbourne-based Opthea Ltd.'s recent A$45 million (US$33.7 million) equity financing will go toward expanding clinical development of its VEGF-C/D trap therapy candidate, OPT-302, for wet age-related macular degeneration (AMD) and diabetic macular edema (DME), aiming to prove additive benefit to existing VEGF-A treatments.